Payment overview · 2025
General Payments
$1,487.47
81 reported records · 20 companies
Healthcare provider profile · identity verified
Michael T Hood, MD
Allopathic & Osteopathic Physicians|Family Medicine · NEWPORT, TN · NPI 1053396432
Verified facts
What the public records show
CMS Open Payments records show Michael T Hood, MD received $1,487.47 in general payments during 2025 across 81 reported records.
Novo Nordisk Inc accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 254 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 254 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $384.20 | 25.8% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $152.85 | 10.3% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $134.71 | 9.1% | 10 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $134.32 | 9.0% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $105.44 | 7.1% | 6 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $74.79 | 5.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $73.06 | 4.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $69.23 | 4.7% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $54.87 | 3.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.33 | 3.4% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.31 | 2.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.55 | 2.7% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $30.95 | 2.1% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $29.99 | 2.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.23 | 1.7% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $23.69 | 1.6% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.14 | 1.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.51 | 1.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.83 | 0.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.47 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,487.47 | 81 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $363.80 | 15 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $231.31 | 13 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $134.32 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $105.44 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $99.25 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $75.18 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $75.18 | 6 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $74.79 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $73.06 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $59.53 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $57.42 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $54.87 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $50.33 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $42.31 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $39.55 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.50 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.44 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $30.95 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $29.99 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| EYLEA Normalized: eylea |
Biological | Regeneron Healthcare Solutions, Inc. | $23.69 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 239 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 43 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 254 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 72 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 156 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 227 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
65 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
254 | 56 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
227 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
254 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
72 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
62 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
156 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
239 | 52 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1027 | 182 |
| Atorvastatin Calcium | Atorvastatin Calcium | 894 | 236 |
| Lisinopril | Lisinopril | 879 | 240 |
| Levothyroxine Sodium | Levothyroxine Sodium | 770 | 181 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 744 | 205 |
| Gabapentin | Gabapentin | 627 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 602 | 178 |
| Montelukast Sodium | Montelukast Sodium | 520 | 145 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 505 | 152 |
| Metoprolol Succinate | Metoprolol Succinate | 489 | 131 |
| Furosemide | Furosemide | 481 | 125 |
| Omeprazole | Omeprazole | 454 | 119 |
| Alprazolam | Alprazolam | 435 | 56 |
| Oxycodone Hcl | Oxycodone Hcl | 430 | 45 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 394 | 103 |
| Fluticasone Propionate | Fluticasone Propionate | 368 | 137 |
| Glimepiride | Glimepiride | 325 | 88 |
| Prednisone | Prednisone | 319 | 135 |
| Allopurinol | Allopurinol | 318 | 75 |
| Potassium Chloride | Potassium Chloride | 318 | 75 |
| Metoprolol Tartrate | Metoprolol Tartrate | 316 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 80 |
| Clopidogrel | Clopidogrel Bisulfate | 281 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 275 | 86 |
| Doxazosin Mesylate | Doxazosin Mesylate | 269 | 70 |
| Meloxicam | Meloxicam | 268 | 82 |
| Famotidine | Famotidine | 258 | 60 |
| Jardiance | Empagliflozin | 254 | 56 |
| Pioglitazone Hcl | Pioglitazone Hcl | 250 | 76 |
| Eliquis | Apixaban | 239 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 239 | 69 |
| Metformin Hcl Er | Metformin Hcl | 238 | 71 |
| Atenolol | Atenolol | 233 | 54 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 228 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 227 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 222 | 37 |
| Tramadol Hcl | Tramadol Hcl | 218 | 38 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 215 | 46 |
| Metformin Hcl | Metformin Hcl | 200 | 56 |
| Ondansetron Odt | Ondansetron | 186 | 71 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 185 | 54 |
| Fluconazole | Fluconazole | 184 | 80 |
| Nateglinide | Nateglinide | 183 | 49 |
| Alendronate Sodium | Alendronate Sodium | 179 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 174 | 35 |
| Pregabalin | Pregabalin | 174 | 30 |
| Buspirone Hcl | Buspirone Hcl | 170 | 44 |
| Promethazine Hcl | Promethazine Hcl | 162 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 161 | 54 |
| Ozempic | Semaglutide | 156 | 36 |
| Carvedilol | Carvedilol | 155 | 47 |
| Indapamide | Indapamide | 151 | 51 |
| Acyclovir | Acyclovir | 145 | 61 |
| Mirtazapine | Mirtazapine | 140 | 34 |
| Ezetimibe | Ezetimibe | 137 | 47 |
| Finasteride | Finasteride | 135 | 37 |
| Oxybutynin Chloride | Oxybutynin Chloride | 134 | 32 |
| Methotrexate | Methotrexate Sodium | 128 | 32 |
| Clonazepam | Clonazepam | 126 | 12 |
| Clonidine Hcl | Clonidine Hcl | 114 | 30 |
| Warfarin Sodium | Warfarin Sodium | 112 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 107 | 19 |
| Azithromycin | Azithromycin | 106 | 85 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 105 | 25 |
| Repaglinide | Repaglinide | 104 | 34 |
| Losartan Potassium | Losartan Potassium | 103 | 37 |
| Leflunomide | Leflunomide | 101 | 27 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 101 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 101 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 99 | 26 |
| Celecoxib | Celecoxib | 97 | 24 |
| Repatha Sureclick | Evolocumab | 97 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 28 |
| Topiramate | Topiramate | 89 | 20 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 81 | 61 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 18 |
| Bupropion Hcl | Bupropion Hcl | 77 | 26 |
| Mupirocin | Mupirocin | 76 | 45 |
| Nitroglycerin | Nitroglycerin | 76 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 22 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 73 | 16 |
| Dexamethasone | Dexamethasone | 72 | 51 |
| Mounjaro | Tirzepatide | 72 | 16 |
| Spironolactone | Spironolactone | 72 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 72 | 17 |
| Xarelto | Rivaroxaban | 72 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 70 | 21 |
| Ibuprofen | Ibuprofen | 70 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 70 | 17 |
| Baclofen | Baclofen | 69 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 67 | 23 |
| Levofloxacin | Levofloxacin | 65 | 41 |
| Linzess | Linaclotide | 65 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 64 | 53 |
| Sumatriptan Succinate | Sumatriptan Succinate | 64 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 17 |
| Meclizine Hcl | Meclizine Hcl | 62 | 22 |
| Trulicity | Dulaglutide | 62 | 14 |
| Ketoconazole | Ketoconazole | 61 | 32 |
| Bupropion Xl | Bupropion Hcl | 60 | 13 |
| Trazodone Hcl | Trazodone Hcl | 59 | 18 |
| Synthroid | Levothyroxine Sodium | 58 | suppressed |
| Lamotrigine | Lamotrigine | 56 | 11 |
| Lorazepam | Lorazepam | 56 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 32 |
| Minoxidil | Minoxidil | 54 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 12 |
| Methocarbamol | Methocarbamol | 52 | 20 |
| Clarithromycin | Clarithromycin | 51 | 16 |
| Benazepril Hcl | Benazepril Hcl | 49 | 11 |
| Diazepam | Diazepam | 49 | 11 |
| Estradiol | Estradiol | 49 | 11 |
| Eszopiclone | Eszopiclone | 49 | suppressed |
| Folic Acid | Folic Acid | 49 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 46 | suppressed |
| Nystatin | Nystatin | 46 | 27 |
| Colesevelam Hcl | Colesevelam Hcl | 45 | 14 |
| Simvastatin | Simvastatin | 45 | 12 |
| Terazosin Hcl | Terazosin Hcl | 45 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 13 |
| Farxiga | Dapagliflozin Propanediol | 43 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 42 | 26 |
| Cefdinir | Cefdinir | 41 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 14 |
| Probenecid-Colchicine | Probenecid/Colchicine | 39 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Digoxin | Digoxin | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Bumetanide | Bumetanide | 36 | suppressed |
| Irbesartan | Irbesartan | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Levetiracetam | Levetiracetam | 34 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 26 |
| Risperidone | Risperidone | 31 | 12 |
| Spiriva Handihaler | Tiotropium Bromide | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 18 |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Metronidazole | Metronidazole | 27 | 16 |
| Ranolazine Er | Ranolazine | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Gemtesa | Vibegron | 26 | suppressed |
| Nabumetone | Nabumetone | 26 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 25 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 21 | 14 |
| Febuxostat | Febuxostat | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 20 | suppressed |
| Roflumilast | Roflumilast | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | 13 |
| Silver Sulfadiazine | Silver Sulfadiazine | 20 | 17 |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Nexletol | Bempedoic Acid | 18 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 18 | suppressed |
| Sulfasalazine | Sulfasalazine | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Flovent Hfa | Fluticasone Propionate | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 12 |
| Desloratadine | Desloratadine | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Ssd | Silver Sulfadiazine | 12 | 11 |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Fluorouracil | Fluorouracil | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Rinvoq | Upadacitinib | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,487.47 · 81 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, ELIQUIS, EYLEA, FARXIGA, GEMTESA, GIVLAARI, GVOKE HYPOPEN, JARDIANCE, Kerendia, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, YUPELRI, ZAVZPRET, ZEPBOUND, ZORYVE | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error